新型糖肽类药物LY 333328对青霉素敏感及耐药肺炎球菌的比较活性
Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci.
作者信息
Fasola E, Spangler S K, Ednie L M, Jacobs M R, Bajaksouzian S, Appelbaum P C
机构信息
Department of Pathology (Clinical Microbiology), Case Western Reserve University, Cleveland, Ohio 44106, USA.
出版信息
Antimicrob Agents Chemother. 1996 Nov;40(11):2661-3. doi: 10.1128/AAC.40.11.2661.
Abstract
Microdilution MIC testing was used to test the susceptibility of 202 pneumococci to LY 333328 and six other agents. LY 333328 was the most active glycopeptide (MIC at which 90% of the pneumococci were inhibited [MIC90], 0.008 microgram/ml), followed by teicoplanin (MIC90, 0.06 microgram/ml) and vancomycin (MIC90, 0.5 microgram/ml). Rifampin resistance was seen in some penicillin-resistant strains. The MICs of imipenem and ceftriaxone rose with those of penicillin. Time-kill testing confirmed the excellent antipneumococcal activity of LY 333328.
摘要
采用微量稀释法进行最低抑菌浓度（MIC）检测，以测试202株肺炎球菌对LY 333328及其他六种药物的敏感性。LY 333328是活性最强的糖肽类药物（90%肺炎球菌被抑制时的MIC[MIC90]为0.008微克/毫升），其次是替考拉宁（MIC90为0.06微克/毫升）和万古霉素（MIC90为0.5微克/毫升）。在一些耐青霉素菌株中发现了对利福平的耐药性。亚胺培南和头孢曲松的MIC随青霉素的MIC升高而升高。时间杀菌试验证实了LY 333328具有出色的抗肺炎球菌活性。
相似文献
1
Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci.新型糖肽类药物LY 333328对青霉素敏感及耐药肺炎球菌的比较活性
Antimicrob Agents Chemother. 1996 Nov;40(11):2661-3. doi: 10.1128/AAC.40.11.2661.
2
MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci.RPR 106972（一种新型口服链阳菌素）、RP 59500（奎奴普丁-达福普汀）、派罗星（RP 7293）、青霉素G、头孢噻肟、红霉素和克拉霉素对10株青霉素敏感和耐药肺炎球菌的抗肺炎球菌活性的最低抑菌浓度（MIC）及时间杀菌研究。
Antimicrob Agents Chemother. 1996 Sep;40(9):2071-4. doi: 10.1128/AAC.40.9.2071.
3
MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents.将GV 118819X（三苯菌素）与其他药物的抗肺炎球菌活性进行的最低抑菌浓度（MIC）和杀菌动力学研究。
Antimicrob Agents Chemother. 1997 Jan;41(1):148-55. doi: 10.1128/AAC.41.1.148.
4
Susceptibility of penicillin-resistant and penicillin-susceptible Streptococcus pneumoniae to newer antimicrobial agents.
J Chemother. 1999 Jun;11(3):191-4. doi: 10.1179/joc.1999.11.3.191.
5
In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae.噁唑烷酮类化合物U - 100592和U - 100766对耐青霉素和耐头孢菌素肺炎链球菌菌株的体外活性
Antimicrob Agents Chemother. 1996 Apr;40(4):1039-40. doi: 10.1128/AAC.40.4.1039.
6
Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents.厄他培南（MK-0826）与其他药物相比的抗肺炎球菌活性。
Antimicrob Agents Chemother. 2002 Jan;46(1):42-6. doi: 10.1128/AAC.46.1.42-46.2002.
7
Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods.采用棋盘法和时间杀菌法测定头孢匹罗和头孢噻肟单独及与万古霉素和替考拉宁联合使用时的抗肺炎球菌活性。
Antimicrob Agents Chemother. 1996 Sep;40(9):1973-6. doi: 10.1128/AAC.40.9.1973.
8
Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies.采用最低抑菌浓度（MIC）和快速杀菌方法测定RP 59500（奎奴普丁-达福普汀）、青霉素G、红霉素和司帕沙星的抗肺炎球菌活性。
Antimicrob Agents Chemother. 1996 Jul;40(7):1653-6. doi: 10.1128/AAC.40.7.1653.
9
Antipneumococcal activity of MEN 10700, a new penem, compared with other compounds, by MIC and time-kill kinetics.通过最低抑菌浓度（MIC）和时间杀菌动力学，将新型青霉烯类药物MEN 10700与其他化合物的抗肺炎球菌活性进行比较。
J Antimicrob Chemother. 1999 Sep;44(3):381-4. doi: 10.1093/jac/44.3.381.
10
MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.DU-6859a、环丙沙星、左氧氟沙星、司帕沙星、头孢噻肟、亚胺培南及万古霉素对9株青霉素敏感及耐药肺炎球菌活性的最低抑菌浓度（MIC）及时间杀菌研究
Antimicrob Agents Chemother. 1996 Feb;40(2):362-6. doi: 10.1128/AAC.40.2.362.
引用本文的文献
1
Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis.LY333328（奥利万星）单独及联合应用治疗耐头孢菌素肺炎球菌性脑膜炎的实验研究
Antimicrob Agents Chemother. 2003 Jun;47(6):1907-11. doi: 10.1128/AAC.47.6.1907-1911.2003.
2
Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin.LY333328对一株对青霉素敏感的肺炎链球菌引起的实验性脑膜炎的活性。
Antimicrob Agents Chemother. 2001 Jul;45(7):2169-72. doi: 10.1128/AAC.45.7.2169-2172.2001.
3
Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains.肺炎链球菌：新型药物对青霉素耐药菌株的活性
Curr Infect Dis Rep. 1999 Apr;1(1):13-21. doi: 10.1007/s11908-999-0004-8.
4
Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.成人社区获得性肺炎管理实践指南。美国传染病学会。
Clin Infect Dis. 2000 Aug;31(2):347-82. doi: 10.1086/313954. Epub 2000 Sep 7.
5
In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.LY333328及对照药物对1997年全球监测研究中收集的医院革兰氏阳性病原菌的体外活性。
Antimicrob Agents Chemother. 2000 May;44(5):1370-4. doi: 10.1128/AAC.44.5.1370-1374.2000.
6
Management of infections due to antibiotic-resistant Streptococcus pneumoniae.耐抗生素肺炎链球菌所致感染的管理
Clin Microbiol Rev. 1998 Oct;11(4):628-44. doi: 10.1128/CMR.11.4.628.
7
In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.新型糖肽类抗生素LY333328对多重耐药革兰氏阳性临床分离株的体外活性
Antimicrob Agents Chemother. 1998 Sep;42(9):2452-5. doi: 10.1128/AAC.42.9.2452.
本文引用的文献
1
Relationship of MICs to efficacy of cefotaxime in treatment of Streptococcus pneumoniae infections.肺炎链球菌感染治疗中头孢噻肟的最低抑菌浓度（MICs）与疗效的关系。
Antimicrob Agents Chemother. 1996 Apr;40(4):895-8. doi: 10.1128/AAC.40.4.895.
2
Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.RPR 106972（一种新型口服链阳菌素）、头孢妥仑（一种新型口服头孢菌素）、两种新型恶唑烷酮（U-100592和U-100766）以及其他口服和胃肠外用药对203株青霉素敏感和耐药肺炎球菌的活性。
Antimicrob Agents Chemother. 1996 Feb;40(2):481-4. doi: 10.1128/AAC.40.2.481.
3
Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae.耐青霉素肺炎链球菌所致脑膜炎的管理
Antimicrob Agents Chemother. 1995 Oct;39(10):2171-5. doi: 10.1128/AAC.39.10.2171.
4
Emergence of drug-resistant pneumococcal infections in the United States.美国耐药肺炎球菌感染的出现。
JAMA. 1994 Jun 15;271(23):1831-5.
5
Comparative activity of teicoplanin and vancomycin against 400 penicillin susceptible and resistant Streptococcus pneumoniae. The French Study Group.替考拉宁与万古霉素对400株青霉素敏感和耐药肺炎链球菌的比较活性。法国研究小组。
Eur J Clin Microbiol Infect Dis. 1994 Jan;13(1):33-4. doi: 10.1007/BF02026121.
6
Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.耐抗生素肺炎链球菌所致感染的管理
N Engl J Med. 1994 Aug 11;331(6):377-82. doi: 10.1056/NEJM199408113310607.
7
Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.采用时间杀菌法对青霉素G、RP 59500、红霉素、司帕沙星、环丙沙星和万古霉素的抗肺炎球菌活性进行比较研究。
Antimicrob Agents Chemother. 1994 Sep;38(9):2065-72. doi: 10.1128/AAC.38.9.2065.
8
Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group.美罗培南与头孢噻肟治疗细菌性脑膜炎的随机对照研究。美罗培南脑膜炎研究组。
Antimicrob Agents Chemother. 1995 May;39(5):1140-6. doi: 10.1128/AAC.39.5.1140.
9
Evaluation of vancomycin for therapy of adult pneumococcal meningitis.万古霉素治疗成人肺炎球菌性脑膜炎的评估。
Antimicrob Agents Chemother. 1991 Dec;35(12):2467-72. doi: 10.1128/AAC.35.12.2467.
10
Antimicrobial resistance in Streptococcus pneumoniae: an overview.肺炎链球菌中的抗菌药物耐药性：概述
Clin Infect Dis. 1992 Jul;15(1):77-83. doi: 10.1093/clinids/15.1.77.
Zotero 插件